HomeCompareKROEF vs ABBV

KROEF vs ABBV: Dividend Comparison 2026

KROEF yields 1190.48% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KROEF wins by $87561745.65M in total portfolio value
10 years
KROEF
KROEF
● Live price
1190.48%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$87561745.75M
Annual income
$75,144,770,262,018.61
Full KROEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KROEF vs ABBV

📍 KROEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKROEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KROEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KROEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KROEF
Annual income on $10K today (after 15% tax)
$101,190.48/yr
After 10yr DRIP, annual income (after tax)
$63,873,054,722,715.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KROEF beats the other by $63,873,054,701,659.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KROEF + ABBV for your $10,000?

KROEF: 50%ABBV: 50%
100% ABBV50/50100% KROEF
Portfolio after 10yr
$43780872.93M
Annual income
$37,572,385,143,395.20/yr
Blended yield
85.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KROEF
No analyst data
Altman Z
24.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KROEF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKROEFABBV
Forward yield1190.48%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$87561745.75M$102.3K
Annual income after 10y$75,144,770,262,018.61$24,771.77
Total dividends collected$86634407.96M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KROEF vs ABBV ($10,000, DRIP)

YearKROEF PortfolioKROEF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$129,748$119,047.62$11,550$430.00+$118.2KKROEF
2$1,582,395$1,443,564.96$13,472$627.96+$1.57MKROEF
3$18,147,032$16,453,869.10$15,906$926.08+$18.13MKROEF
4$195,767,126$176,349,802.56$19,071$1,382.55+$195.75MKROEF
5$1,987,444,676$1,777,973,850.42$23,302$2,095.81+$1987.42MKROEF
6$18,995,858,497$16,869,292,693.68$29,150$3,237.93+$18995.83MKROEF
7$171,012,980,425$150,687,411,833.19$37,536$5,121.41+$171012.94MKROEF
8$1,450,820,667,844$1,267,836,778,790.02$50,079$8,338.38+$1450820.62MKROEF
9$11,604,649,992,886$10,052,271,878,292.46$69,753$14,065.80+$11604649.92MKROEF
10$87,561,745,754,407$75,144,770,262,018.61$102,337$24,771.77+$87561745.65MKROEF

KROEF vs ABBV: Complete Analysis 2026

KROEFStock

KR1 Plc, a digital asset investment company, trades in the blockchain technology sector. It supports early stage decentralized and open source blockchain projects. The company was formerly known as Kryptonite 1 plc and changed its name to KR1 Plc in February 2018. KR1 Plc was incorporated in 2006 and is based in Douglas, Isle of Man.

Full KROEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KROEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KROEF vs SCHDKROEF vs JEPIKROEF vs OKROEF vs KOKROEF vs MAINKROEF vs JNJKROEF vs MRKKROEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.